Evaluating the Response of the Immune System of People with Long COVID (post SARS-CoV-2)
At a glance
Conditions
NCT05131594
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Huntington Hospital
Pasadena, Californiano site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Kimberly Shriner, MD · PRINCIPAL_INVESTIGATOR · Huntington Hospital
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Correlation of symptomatology with inflammatory profiles in patients with Post-Acute Sequelae of SARS-CoV2 (PASC)From onset of infection to 24 months
Do patient symptoms correlate with abnormalities in inflammatory profiles?
- Identification of immunologic and inflammatory features of PASC based on results of immunologic and inflammatory assaysFrom onset of infection to 24 months
Are there abnormalities in immunologic and inflammatory assays unique to PASC?
- Evaluation and delineation of the pathologic pathways and long-term effects of SARS-CoV2 infectionFrom onset of infection to 60 months
What are the pathological pathways and long-term effects of SARS-CoV2?
- Identification of risks factor for PASCFrom onset of infection to 24 months
What are the risk factors for PASC?
- Identification of potential sites of therapeutic intervention to ameliorate symptomatology of PASCFrom onset of infection to 60 months
Are there potential sites of therapeutic intervention to relieve the symptoms of PASC?